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Background: During the follow-up in a randomized controlled trial, participants may receive 
additional (non-randomly allocated) treatment that affects the outcome. Typically, such additional 
treatment is not taken into account in the evaluation of the results. Two pivotal trials of the effects 
of hemodiafiltration (HDF) versus hemodialysis (HD) on mortality in patients with end-stage renal 
disease reported differing results. We set out to evaluate to what extent methods to take other 
treatments (i.e. renal transplantation) into account may explain the difference in findings between 
RCTs. This is illustrated using a clinical example of two RCTs estimating the effect of HDF versus HD 
on mortality.  
Methods: Using individual patient data from the ESHOL (n=902) and CONTRAST (n=714) trials, five 
methods for estimating the effect of HDF versus HD on all-cause mortality were compared: intention-
to-treat (ITT) analysis (i.e., not taking renal transplantation into account), per protocol exclusion 
(PPexcl; exclusion of patients who receive transplantation), PPcens (censoring patients at time of 
transplantation), transplantation-adjusted (TA) analysis, and an extension of the TA analysis (TAext) by 
additional adjustment for variables related to both risk of receiving a transplantation and the risk of 
an outcome (transplantation-outcome confounders). Cox proportional hazards models were applied.  
Results: Unadjusted ITT analysis of all-cause mortality led to differing results between CONTRAST 
and ESHOL: HR 0.95 (95%CI 0.75-1.20) and HR 0.76 (95%CI 0.59-0.97), respectively: difference 
between 5% and 24% risk reduction. Similar differences between the two trials were observed for 
the other unadjusted analytical methods (PPcens, PPexcl, TA) The HRs of HDF versus HD treatment 
became more similar after adding transplantation as a time varying covariate and including 
transplantation-outcome confounders: HR 0.89 (95%CI 0.69-1.13) in CONTRAST and HR 0.80 (95%CI 
0.62-1.02) in ESHOL.  
Conclusions: The apparent differences in estimated treatment effects between two dialysis trials 
were to a large extent attributable to differences in applied methodology for taking renal 
transplantation into account in their final analyses. Our results exemplify the necessity of careful 
consideration of the treatment effect of interest when estimating therapeutic effect in randomized 
controlled trials in which participants may receive additional treatments.   
 
Keywords:  end-stage renal disease – hemodiafiltration – randomized controlled trial – renal 
transplantation – time-varying exposure 
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Short summary 
 Methods for handling competing treatments in trials lead to effect estimates with differing 
causal interpretations. 
 In order to obtain an effect estimate for a therapy that is independent of the effect a therapy 
has through affecting (the probability of) another treatment, researchers should include 
competing treatment as a time-varying covariate in the model for the outcome. 
 When competing treatment is included as a time-varying covariate in the model for the 
outcome, researchers should also adjust for variables related to both competing treatment 
and the outcome (TAext). 
 This approach explained to a large extent the differences in results between ESHOL and 
CONTRAST studies, i.e., a difference between RCT results in relative risk reduction of 19% 




The randomized controlled trial (RCT) is the preferred design to assess the effects of medical 
treatments. When patients switch to the other trial treatment arm, receive additional treatment that 
is not randomly allocated, or stop their treatment, estimation of treatment effects may not be 
straightforward, notably when treatment switching depends on patient characteristics [1]. 
In RCTs comparing hemodiafiltration (HDF) with hemodialysis (HD) on the risk of mortality among 
patients with end stage kidney disease (ESKD), during follow-up a subset of patients may receive 
another (non-randomly allocated) treatment that effectively improves patient outcome. For 
example, renal transplantation is highly effective in reducing mortality risk in ESKD patients and 
differences in handling renal transplantation during follow-up in the analysis of a trial may lead to 
different results [2]. Two pivotal dialysis trials reported conflicting findings: results of the ESHOL trial 
indicated improved survival for HDF compared to HD (all-cause mortality HR 0.70; 95%CI 0.53-0.92), 
while results from the CONTRAST analysis reported no difference in mortality between treatment 
groups (HR 0.95; 95%CI 0.75-1.20) [3, 4]. These differing results may be explained by a number of 
differences between the trials. Notably, in the original ESHOL study patients were censored at the 
time of  renal transplantation, so no patient information on all-cause mortality was collected after 
renal transplantation. [4]. Such loss to follow-up may introduce bias if censoring is associated with 
the allocated treatment and the risk of the outcome [1, 5]. Alternatively, in the CONTRAST trial 
participants were followed-up for the primary outcome (i.e. all-cause mortality), irrespective of a 
renal transplantation and the effects of the dialysis treatments were estimated based on an 
intention-to-treat analysis (and ignoring transplantation) [3]. Furthermore, none of the trial analyses 
took renal transplantation into account. 
Post-randomization renal transplantation may induce differences in patient characteristics between 
treatment groups in dialysis trials, since the probability of receiving a renal transplantation may not 
only depend on patient characteristics, but also on the randomly allocated treatment a patient 
receives (here: on the dialysis modality). For example, patients treated with HDF may more often 
receive a renal transplant compared to patients treated with HD (e.g. when HDF brings patients in a 
better shape for transplantation). As a result, in dialysis trials, the probability of receiving a 
transplant may differ between treatment arms. Therefore, restricting the analysis to those who did 
not undergo a renal transplantation (e.g. in a per protocol analysis), may result in incomparable 
treatment groups. As an example, assume that 20% of HDF treated patients receives a renal 
transplantation, compared to 10% of HD treated patients and that transplantation is more likely in 
younger patients. Due to the randomization procedure, the age distribution at baseline of patients 
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receiving HDF or HD is comparable. However, restricting the analysis to those patients who did not 
undergo a renal transplantation, leads to excluding a larger proportion (20%) of patients (who are on 
average younger) in the HDF treatment group, compared to the (10%) of patients in the HD 
treatment group. The remaining patients in the HDF treatment group are on average older than the 
patients in the HD treatment group, a situation referred to as confounding, because age is now 
associated with treatment as well as the outcome (here: survival). 
In other words, if treatment increases the probability to receive a renal transplant and risk factors for 
the outcome (mortality) are also related to receiving renal transplantation, restricting the data 
analysis to those patients who did not receive a transplantation (or similarly, adjusting for 
transplantation) may distort the balance between treatment groups achieved by randomization (See 
Figure 1). If the selection of patients for the analysis (e.g. non-transplanted patients) differs between 
treatment groups (i.e. if patients in one of the two comparison groups are more likely to receive 
transplantation), the effect estimate will be biased [6]. When the assigned treatment is, however, 
not related to the competing treatment (renal transplantation), but the competing treatment does 
affect the absolute risk of the outcome (survival), generally the relative risk will be correct, although 
the precision of the estimate is reduced (i.e., larger confidence intervals). A priori we did not know 
whether transplantation rates would differ between treatment arms. However, since transplantation 
is a very effective competing treatment, we expected that even slight differences (e.g. due to chance) 
could influence results. 
When the mechanism of allocating transplant kidneys differs between studies, this may contribute to 
differences in effect estimates between studies depending on the applied method of analysis. To 
study the value of taking competing risks into account when evaluating therapy effect, we set out to 
determine to what extent approaches that take competing risks (i.e., renal transplantation) into 
account may explain the conflicting findings between these two trials. 
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SUBJECTS AND METHODS 
 
Data design and study population 
Individual patient data from the CONTRAST and ESHOL studies were used for the current study. 
Detailed descriptions of the study designs, patient characteristics, and treatment procedures of each 
of the studies have been reported elsewhere [3][4][7][8]. In the ESHOL study patients who received a 
renal transplant had been censored alive in the previously published analyses, an approach 
potentially leading to bias. The ESHOL dataset was completed by adding follow-up data on all-cause 
mortality for those patients who had discontinued randomized treatment (received a renal 
transplant), as described previously [7][9Error! Reference source not found.]. The ESHOL study 
included 906 patients; 456 were randomized to receive HDF and 450 to HD. Median follow-up time 
was 3 years (range 0.01, 3.08) [4]. The CONTRAST study included 714 patients; 358 received HDF and 
356 were allocated to HD. Median follow-up time was 2.90 years (range 0.04-6.56) [3]. Due to 
missing outcome and time of transplantation data, four patients were excluded from the current 
analysis of the ESHOL dataset. 
Given a large sample size, randomization is expected to create treatment groups that are on average 
comparable with respect to patient characteristics, i.e. treatment is independent of patient 
characteristics. Receiving a renal transplantation, however, may be dependent on patient 
characteristics. For example, younger patients with less co-morbidity are more likely to receive a 
renal transplantation. These patient characteristics are also predictive of the outcome (all-cause 
mortality). Since these patient characteristics are related to both transplantation and the outcome 
we will refer to them as confounders of the transplantation-outcome relation (See Figure 1). 
While randomization is expected to achieve equal distributions of patient characteristics between 
treatment arms, in reality differences in patient characteristics may actually be present. Adjustment 
for variables related to the outcome will remove any remaining confounding by observed variables 
and tends to improve power in all mentioned methods of analysis [10]. 
 
Methods to analyze dialysis trials in the presence of renal transplantation 
We compared five methods to handle renal transplantation in dialysis trials. These methods are 
described in more detail below and summarized in Table 1. 
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1 Intention-to-treat (ITT) analysis 
In ITT analysis, patients are analyzed according to the treatment group they are allocated to. This 
analysis ignores the fact that a subgroup of patients received a renal transplantation and stopped the 
allocated treatment. We are not taking into account other forms of treatment switching (e.g. from 
HD to HDF or the other way around). Since the equal distributions of patient characteristics 
(including those also associated with the outcome) between treatment groups obtained by 
randomization remains intact, ITT analysis allows for unbiased effect estimation. The ITT estimate is 
interpreted as the effect of the treatment strategy; implying that renal transplantation during the 
follow-up period of the trial is an inherent part of the treatment strategy. In other words, results 
from the current study will not be applicable to a future population in which the proportion of 
patients receiving a renal transplantation and / or the patient characteristics of those receiving a 
transplantation (i.e. the strategies) differ from those in the current trial. ITT treatment effects are 
sometimes called pragmatic or total effects, since the ITT estimate includes the effect treatment has 
through changing the probability of receiving additional interventions (including here a renal 
transplantation) after the treatment has been initiated.  
 
2 Per protocol exclusion (PPexcl) analysis 
Similar to ITT analysis, in PP analysis patients are analyzed according to the treatment group they 
were allocated to. However, in PPexcl analysis those subjects who stop receiving their allocated 
treatment after receiving a renal transplantation,  are excluded from the analysis. The PP estimate is 
interpreted as the effect of treatment in the subset of patients that complete the trial according to 
protocol (here, non-transplanted patients). Besides the fact that renal transplantation improves 
survival, patients receiving renal transplantation have a different prognosis (e.g. these patients are 
on average younger) compared to patients who remain on treatment, therefore PP analyses are 
biased in case transplantation occurs more often in one of the treatment groups [1, 11]. However, 
when these prognostic differences (i.e. confounders of the transplantation-outcome relation) are 




3 Per protocol censoring (PPcens) analysis 
In a PPcens analysis, patients receiving a renal transplantation are not excluded from the analysis (as in 
the PPexcl analysis), but censored (i.e considered excluded without developing the outcome) at the 
time they receive the transplantation. Similar to PPexcl , PPcens analyses are biased in case 
transplantation occurs more often in one of the treatment groups and the reasons for this are 
associated with the outcome. However, the bias is less pronounced compared with PPexcl, since 
patient-time until transplantation is still accounted for in the analysis. Again, adjustment for 
confounding leads to an unbiased effect estimate, provided no other sources of bias exist. 
 
4 Including transplantation in the outcome model, transplantation adjusted (TA) analysis 
Treatment effects obtained by ITT and PP may be of limited generalizability. Specifically, PP effects 
are only applicable to patients who do not receive transplantation, and ITT effects are only 
generalizable to populations with a comparable percentage and allocation mechanism of 
transplantation. Therefore it may be of interest to estimate the controlled direct effect of treatment, 
which is the effect of treatment (i.e., dialysis) excluding the effect treatment has through changing 
the probability of receiving a renal transplantation (either by chance or through some causal, known 
or unknown, mechanism) [12]. The controlled direct effect of treatment assumes the same effect of 
treatment in patients receiving transplantation as well as non-transplanted patients [13]. The 
controlled direct effect is estimated by including transplantation in the outcome model. The 
transplanted-adjusted (TA) estimates can be interpreted as the biological effect of treatment on the 
outcome, independent of the effect of treatment through affecting the probability of a 
transplantation. Transplantation should be modelled as a time-dependent covariate in the outcome 
model [14, 15].  
 
5 TA analysis adjusted for transplantation-outcome confounders (TAext) 
Since TA effect estimates are conditional on transplantation, the resulting effect estimates are prone 
to bias (as in the PP analysis). Therefore, it is necessary to adjust for transplantation-outcome 
confounders in the outcome model. The TAext effect may be biased if important confounders for the 
relationship between transplantation and the outcome are unmeasured or when observed 
confounders were not assessed correctly. In our analyses we adjusted for measured confounders: 
age, history of cardiovascular disease, serum creatinine, diabetes mellitus, hemoglobin, albumin, 





R 3.0.1 (www.r-project.org) was used to perform the statistical analyses [16]. Before applying the five 
methods of analysis described above, missing data on transplantation-outcome confounders were 
imputed using multiple imputation by chained equations using the R-package “mice” [17]. Log 
transformations of months of dialysis and c-reactive protein were taken to comply with the 
assumption of normality, which is necessary for multiple imputation. Ten imputed datasets were 
created for each study. The R-package “survival” was used to fit the Cox proportional hazard (PH) 
models. Cox PH models were applied. When transplantation was included in the Cox PH model, it 
was included as a time-varying covariate in order to prevent immortal-time bias. Immortal-time bias 
is the result of classifying patient-time, before onset of treatment, as time on treatment. Because 
patients have to survive until they receive the treatment of interest, the misclassified time before the 
start of treatment is called immortal-time, and the resulting bias immortal-time bias [14, 15, 18, 19]. 
Results from the imputed datasets were combined using Rubin’s rule to obtain hazard ratios (HRs) 
and 95% confidence intervals (CI) [20], for which the function MIcombine from the package “mitools” 






Baseline characteristics of patients enrolled in the ESHOL and CONTRAST studies are presented in 
Table 2. A total of 28,326 observation months from 902 patients were included in the analysis of the 
ESHOL study. The mean age of patients was 65.5 years (sd 14.3 years) and 298 (33.0%) had a history 
of cardiovascular disease. A total of 179 (19.8%) patients received a renal transplantation during 
follow-up, 101 (22.2%) HDF patients were transplanted compared to 78 (17.5%) HD patients. Missing 
covariate data were most common for c-reactive protein, which had missing entries for 211 (23.4%) 
patients. The CONTRAST study consisted of 26,398 observation months from 714 patients. The mean 
age of patients was 64.1 years (sd 13.7 years) and 313 (43.8%) had a history of cardiovascular 
disease. During follow-up, 151 (21.1%) patients received a renal transplantation, 78 (21.8%) HDF 
versus 73 (20.5%) HD patients were transplanted. Again, missing covariate data were most prevalent 
for c-reactive protein, on which 309 (43.3%) patients had missing entries. 
 
As expected, in both ESHOL and CONTRAST, baseline characteristics of patients receiving 
transplantation during follow up differed from patients who did not receive a renal transplant (Table 
2). In the non-transplanted patient group of the ESHOL study, treatment groups differed with respect 
to history of cardiovascular disease (HD 38.0%, HDF 34.9%) and diabetes mellitus status (HD 29.3%, 
HDF 25.4%). In the CONTRAST study,  transplantation-outcome confounders were comparable in the 
two treatment groups. For example,  the prevalence of a history of cardiovascular disease  (HD 50.9% 
vs HDF 48.6%) and diabetes mellitus (25.2% HD vs 26.8% HDF) were similar. 
 
Table 3 shows the effect of HDF treatment against HD treatment on all-cause mortality, when 
applying different analytical methods in the two  studies. In ESHOL, the effect of HDF vs HD 
treatment was estimated to be HR 0.76 (95%CI 0.59-0.97) for the unadjusted ITT. In CONTRAST, the 
effect of HDF vs HD treatment was estimated to be HR 0.95 (95%CI 0.75-1.20) for the unadjusted ITT.  
 
Unadjusted PP analysis of the ESHOL study resulted in HR 0.73 (95% CI 0.56-0.94) and HR 0.74 (95%CI 
0.58-0.96) for censoring (PPcens) and exclusion (PPexcl), respectively. In the CONTRAST study, the 
unadjusted PP analyses resulted in HR 0.88 (95%CI 0.69-1.13) and HR 0.90 (95%CI 0.70-1.16) for 
PPcens and PPexcl, respectively.  
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In ESHOL, TA analysis resulted in HR 0.77 (95%CI 0.60-0.99), while TA analysis in the CONTRAST study 
resulted in HR 0.95 (95%CI 0.75-1.21). In ESHOL, TA analysis with adjustment for transplantation-
outcome confounders (TAext) resulted in HR 0.80 (95%CI 0.62-1.02), while the same analysis in the 
CONTRAST study resulted in HR 0.89 (95%CI 0.69-1.13).  
 
DISCUSSION 
This study assessed whether differences in published effect estimates observed between two RCTs 
(ESHOL and CONTRAST) investigating the effect of HDF versus HD on mortality in end-stage renal 
disease could be attributed to the fact that these RCTs applied different methods of analyzing the 
occurrence of renal transplantation during the trial. Indeed, the differences in effects between the 
two studies attenuated when the same analysis was performed; especially adjustment for 
transplantation-outcome confounders led to more similar effect estimates between the ESHOL and 
CONTRAST trials. This indicates that differences in applied analytical methods explain part of the 
differences in effects observed between these trials. Our analyses exemplify the necessity of taking 
competing treatments into accounting when evaluating effects of therapeutic interventions in 
randomized trials.  
 
Strengths and limitations 
One of the strengths of our study is that by using the original individual patient data we were able to 
compare different methods of analysis in the same data, such that differences in results obtained are 
likely due to the method applied. However our study is limited by the fact that, apart from the 
method of analysis, varying results between RCTs in end stage renal disease patients may be 
explained by other factors, such as differences in patient characteristics, random sampling variability, 
variation between practices, and the dosage/intensity of the delivered intervention as has been 
discussed at length in the literature [2][5][21]. These issues are beyond the scope of this paper.  
 
In the current analysis , only confounders (patient characteristics) that were measured at baseline 
were considered. Adjustment for baseline patient characteristics ignores the fact that patient 
characteristics, including confounders of the transplantation-outcome relation, may change over 
time. When treatment affects future patient characteristics and these (intermediate) patient 
characteristics increase the probability of transplantation, adjusted TA analysis adjusting for baseline 
transplantation-outcome confounders only may be biased, since these patient characteristics may 
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have changed over time. However, adjustment for time-varying transplantation-outcome 
confounders affected by prior treatment (dialysis) should not be performed using standard methods 
such as stratification or regression analysis [6, 22]. In that case, advanced methods, such as inverse 
probability of treatment weighting (IPTW), G-computation, or G-estimation, could be used to obtain 
unbiased effect estimates. Additionally, treatment by competing treatment interactions may need to 
be explored [13]. 
 
Choosing the direct effect of HDF (TAext) over a pragmatic effect (ITT)  
In practice, we often want to estimate the effect of the package of care a ESRD patient receives 
(including either HDF or HD) on the risk of mortality. It seems that this effect is estimated by the total 
effect of HDF compared to HD, based on an ITT analysis, which includes the increase in 
transplantation likelihood, and through that a reduction in the risk of mortality. However, when we 
assume that HDF and HD patients within a particular trial are competing for receiving a 
transplantation due to the limited amount (e.g. they are fishing in the same pool) of available renal 
donors, the estimated ITT effect may differ from the effect that will be encountered in  the 
population receiving future daily practice (i.e. in the target population). In other words, the ITT effect 
may not exist outside the trial environment. We will try to illustrate this using some figures from the 
ESHOL trial. In the ESHOL trial, a total of 179 (19.8%) patients received a renal transplantation during 
follow-up; relatively more patients in the HDF group (22.2%) received transplantation compared to 
the HD group (17.5%). Therefore, part of the observed ITT effect comparing HDF to HD is due to the 
larger percentage of renal transplantation in the HDF group. However, when we assume that the 
total number of transplantations performed in that population does not increase under HDF 
treatment (it is unlikely that the number of transplantations will increase, since the number of 
transplantations performed is limited by the amount of donors available and this amount is 
unrelated to the treatment at hand) we expect 19.8% of patients to receive a transplantation if we 
decide to treat the target population with one of the two strategies (HDF or HD).This would mean 
that an expected 19.8% of patients on HDF treatment will receive a transplantation and similarly in 
the same population on HD treatment also an expected 19.8% of patients will receive a 
transplantation. Therefore, the indirect effect of HDF included in the ITT effect (i.e., the effect of HDF 
on the risk of mortality through increasing the likelihood of transplantation relative to HD within a 
trial) will not provide health benefits in the target population, since the total number of 
transplantations performed under HDF does not increase compared to the situation in which all 
patients are treated with HD. In other words, the effect of HDF treatment in the target population is 
different from the effect estimated by ITT analysis in a trial, because the indirect effect of HDF does 
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not exist in the target population. Therefore, models such as TAext should be applied that assess the 
direct effect of HDF on the risk of mortality. With the following exaggerated example we wish to 
further illustrate our point. Imagine the situation that a total of 20% of trial patients receive a 
transplantation, relatively more (40%) of patients in the HDF group received a transplantation 
compared to (0%) in the HD group. Again the ITT effect will indicate benefits of HDF compared to HD, 
largely due to the indirect effect caused by the transplantations performed in the HDF group and 
partly due to the direct effect of HDF on mortality. However, when HDF would be applied to all 
patients in the target population, 20% of HDF patients will receive a transplantation and when we 
compare their outcome to the outcome of the same population under HD treatment in which also 
20% would receive transplantation we would conclude that part of the indirect effect observed in the 
trail remains unobserved in the target population. 
 
Additionally, the replicability of the ITT effect in another study is compromised when other study 
populations have different proportions of patients receiving renal transplantation and/or the patient 
characteristics of those receiving transplantation differ from those in the current trial. It may be 
easier to generalize the effects of HDF vs HD based on their direct effects on mortality. Therefore, of 
the methods we considered, the direct effect of HDF on mortality estimated by TAext can be 
considered most generalizable to populations where the proportions of patients receiving renal 
transplantation and/or the patient characteristics of those receiving transplantation differ from 
those in the ESHOL and the CONSTRAST trial.  
 
Hence, the reasons for choosing the direct effect (TAext) of HDF over a pragmatic effect (ITT) are 
twofold. First, the ITT effect consists of a comparison between treatment groups within a trial. 
Therefore, if one group receives more transplantations, the other necessarily receives less. This 
situation does not exist outside the trial environment, therefore the ITT effect may differ from the 
effect that will be observed in the target population. . Second, the replicability of the ITT effect is 
compromised when other study populations have different proportions of patients receiving renal 
transplantation and/or the patient characteristics of those receiving transplantation differ from 
those in the current trial. However, the TAext effect may be biased if important confounders for the 
relationship between transplantation and the outcome are unmeasured or when observed 
confounders were not assessed correctly. Therefore we propose to report both TAext and ITT 







The apparent differences in estimated treatment effects between two dialysis trials were to a large 
extent attributable to differences in applied methodology for taking renal transplantation into 
account in their final analyses. Our results exemplify the necessity of careful consideration of the 
treatment effect of interest when estimating therapeutic effect in randomized controlled trials in 
which participants may receive additional treatments. 
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TABLES 
TABLE 1 Methods to deal with transplantation during follow-up (competing treatment) in randomized trials of hemodialysis 
Method Description Interpretation of effect estimate Potential for bias 
Intention to treat (ITT) Data of all patients is used. Treatment 
status is analyzed as allocated. 
Transplantation is ignored in the analysis. 
The effect of treatment in settings with rates and 
allocation mechanisms of transplantation similar 
to the current trial. 
Unbiased when randomization is successful. 
Per protocol (PP) (Exclusion) Exclude patients who receive 
transplantation from the analysis. 
The effect of treatment in the group that 
completes the trial according to protocol (i.e. 
patients who do not receive transplantation). In 
other words, the effect of treatment in non-
transplanted patients. 
This effect is biased when both treatment affects 
the probability to receive transplant and 
transplantation-outcome confounders are 
present. Bias can be avoided by adjusting for 
transplantation-outcome confounders. 
Per protocol (PP) (Censored) Censor patients who receive 
transplantation at transplantation (follow-
up info after transplantation is discarded). 
See per protocol exclusion. Difference is that we 
gain the patient-time until transplantation for 
patients receiving transplantation. This may lead 
to narrower confidence intervals. 
See per protocol exclusion. 
Accounting for transplant as 
time-dependent covariate 
(TA) 
Transplantation is added to the outcome 
model as a time-dependent covariate. 
The effect of treatment in transplanted and non-
transplanted patients. 
This effect is biased when treatment affects the 
probability to receive transplant and there are 
transplantation-outcome confounders. Bias can 
be avoided by adjusting for transplantation-
outcome confounders. 
Accounting for transplant as 
time-dependent covariate 
and adjustment for 
transplantation-outcome 
confounders (TAext) 
Transplantation is added to the outcome 
model as a time-dependent covariate. 
Additionally, confounders of the 
transplantation outcome relationship are 
included in the model for the outcome.  
The effect of treatment in transplanted and non-
transplanted patients. 
 The TAext effect is biased when important 
transplantation-outcome confounders are 
unmeasured or unknown and therefore cannot 
be adjusted for. 
 
In RCTs comparing hemodiafiltration (HDF) with hemodialysis (HD) on the risk of mortality among patients with end stage kidney disease (ESKD), during follow-up a subset of patients may receive a non-randomly 
allocated competing treatment (i.e. a renal transplantation) that effectively improves patient outcome.
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TABLE 2 Baseline characteristics of patients in CONTRAST and ESHOL  
 CONTRAST ESHOL 
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Due to the nature of MI and rounding of numbers, the separate DM categories do not 
sum to the overall DM count.  
 
Due to the nature of MI and rounding of numbers, the separate DM categories do not sum to the overall DM count.  
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TABLE 3 Estimates of the hazard ratio (HR) of hemodiafiltration (HDF) versus hemodialysis (HD)  for all-cause mortality for different methods in 
two RCTs: ESHOL and CONTRAST 
 ESHOL CONTRAST 
Method HR (95% CI) HR (95% CI) 
Intention to treat (ITT) 0.76 (0.59-.97) 0.95 (0.75-1.20)§CONTRAST 
Per protocol (PP) (Censored) 0.73 (0.56-0.94)§ESHOL 0.88 (0.69-1.13) 
Per protocol (PP) (Exclusion) 0.74 (0.58-0.96) 0.90 (0.70-1.16) 
Accounting for transplant as a  time-dependent 
covariate (TA) 
0.77 (0.60-0.99) 0.95 (0.75-1.21) 
Accounting for transplant as a  time-dependent 
covariate and adjustment for transplantation-
outcome confounders (TAext) 
0.80 (0.62-1.02) 0.89 (0.69-1.13) 
§ original ESHOL and CONTRAST analyses. For the current analyses, the ESHOL dataset was completed by adding follow-up data on all-cause mortality for those patients who had discontinued randomized treatment 




Figure 1. Causal diagram of renal transplantation in randomized controlled trials of dialysis modalities.  
When treatment is related to receiving a transplantation, and patient characteristics (transplantation-outcome 
confounders) are related to both transplantation as well as experiencing the outcome. Selection bias arises when only 
patients who did not receive a transplantation are selected for analysis (or similarly, when we condition on-, or adjust for- 
transplantation). Since patient characteristics for patients receiving a transplantation are different from those who do not 
receive a transplantation. And a different proportion of patients in each treatment group receives a transplantation, the 
remaining treatment groups are no longer comparable on these transplantation-outcome confounders. The induced bias is 
a result of selection of patients for analysis (i.e. non-transplanted patients) which is different between treatment groups 
(i.e. patients in the treatment group are more likely to receive transplantation), and is therefore called selection bias. 
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